GLP-3 RTA vs MOTS-C
GLP-3 RTA and MOTS-C are both studied in weight research, but they are different classes of compound with different reported research applications.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do GLP-3 RTA and MOTS-C differ?
GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research; MOTS-C (Mitochondrial-derived 16-amino-acid peptide) is catalogued under weight & metabolic research. Verve lists 5 reported research applications for GLP-3 RTA and 5 for MOTS-C. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | GLP-3 RTA | MOTS-C |
|---|---|---|
| compound class | Synthetic triple-agonist peptide | Mitochondrial-derived 16-amino-acid peptide |
| research area | weight & metabolic | weight & metabolic |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg · 20mg · 30mg | 10mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $142.99 | $78.99 |
| availability | in stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is GLP-3 RTA and what is MOTS-C?
GLP-3 RTA is classified as Synthetic triple-agonist peptide; MOTS-C as Mitochondrial-derived 16-amino-acid peptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →MOTS-C
Mitochondrial-derived 16-amino-acid peptide
MOTS-c is a 16-amino-acid peptide encoded not by nuclear DNA but by a short open reading frame within the mitochondrial 12S rRNA gene. It belongs to the mitochondrial-derived peptide family, a group of small peptides that are of interest in research precisely because their genetic origin sits inside the organelle rather than the nucleus.
full MOTS-C profile →Which research models is each compound studied in?
GLP-3 RTA and MOTS-C both sit inside weight & metabolic research, so their listed models share framing while differing in specifics. The table lists 5 reported research applications for GLP-3 RTA and 5 for MOTS-C. Rows are per compound, not equivalences.
| GLP-3 RTA — reported research applications | MOTS-C — reported research applications |
|---|---|
| GLP-1, GIP, and glucagon receptor agonism research | Mitochondrial-derived peptide and retrograde-signaling research |
| cAMP and class B GPCR signaling research models | AMPK pathway research models |
| Comparative single-, dual-, and triple-agonist pharmacology studies | One-carbon (folate–methionine) metabolism studies |
| Metabolic-pathway and nutrient-handling research models | Cellular energy-metabolism and substrate-utilization research |
| Peptide half-life, lipidation, and stability research | Exercise-physiology and metabolic-stress research models |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for GLP-3 RTA and MOTS-C?
GLP-3 RTA is listed from $142.99 and MOTS-C from $78.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
| MOTS-C | 10mg | $78.99 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about GLP-3 RTA and MOTS-C
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
What is MOTS-C?
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial genome. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is MOTS-C studied for in research?
It is used in mitochondrial-signaling research, including AMPK pathway activity, one-carbon metabolism, and retrograde signaling between mitochondria and the nucleus in in-vitro and pre-clinical models. Verve makes no health claims.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.